Share this article:

Valeant Pharmaceuticals International said Tuesday that it completed enrolling patients in a second third-phase clinical trial for retigabine, an epilepsy drug the company is looking to for growth...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to archives
  • Book of Lists — the most comprehensive business resource in Orange County
  • NEW: Orange County 500 — influential business leaders you need to know
Yours for only $99